Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
26,538
Total Claims
$5.3M
Drug Cost
590
Beneficiaries
$8,922
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+532%
Cost per patient vs peers
$8,922 vs $1,411 avg
+177%
Brand preference vs peers
29.4% vs 10.6% avg
🔎 Data Overview
Cost per patient is 532% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 7,678 claims · $4.8M
Generic: 18,419 claims · $491K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,702 | $771K |
| Diclofenac Epolamine | 1,155 | $651K |
| Denosumab | 253 | $438K |
| Linaclotide | 618 | $403K |
| Vortioxetine Hydrobromide | 543 | $330K |
| Empagliflozin | 342 | $260K |
| Lipase/Protease/Amylase | 229 | $211K |
| Sitagliptin Phosphate | 227 | $168K |
| Lipase/Protease/Amylase | 145 | $167K |
| Mirabegron | 303 | $162K |
| Linagliptin | 184 | $130K |
| Icosapent Ethyl | 410 | $124K |
| Semaglutide | 96 | $123K |
| Cyclosporine | 128 | $95K |
| Apixaban | 112 | $88K |
Prescribing Profile
Patient Profile
76
Avg Age
60%
Female
1.13
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data